AMSTERDAM—Johnson & Johnson said Friday it is in advanced negotiations to buy Crucell NV for €1.75 billion ($2.29 billion), a move that would make the Dutch biotechnology company the core of its vaccine business.
U.S.-based J&J already owns 17.9% of Crucell, but wants full control so that it can develop and commercialize the Dutch company’s pipeline of vaccines.
To read more, please follow this link.
